Workflow
华益泰康IPO辅导进展:投资机构派驻董事调整,新聘85后董事王进
Sou Hu Cai Jing·2025-08-17 01:23

Core Viewpoint - Huayi Taikang Pharmaceutical Co., Ltd. is progressing with its IPO guidance, with the guidance period set from April 1, 2025, to June 30, 2025, after starting the IPO filing on January 26, 2024 [2] Company Overview - Huayi Taikang was established in June 2010, focusing on the research, development, production, and sales of complex formulations and innovative formulations, providing one-stop, international pharmaceutical R&D and customized production services [3] - The company has a registered capital of 60.048 million yuan and is legally represented by Zhu Honggang [3] Product Portfolio - The main products approved for sale include sustained-release metoprolol succinate tablets, enteric-coated paroxetine sustained-release tablets, tacrolimus capsules, enteric-coated esomeprazole magnesium capsules, and agomelatine tablets, primarily used in treating hypertension, depression, organ transplantation, digestive system, and neurological diseases [4] Financial Performance - Revenue for Huayi Taikang from 2022 to 2024 was 113 million yuan, 258 million yuan, and 308 million yuan respectively, with net profits of -40.59 million yuan, 65.64 million yuan, and 59.40 million yuan [5] - In Q1 2025, the company reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, a year-on-year increase of 175.71% [6][8] - The basic earnings per share for Q1 2025 was 0.47 yuan, compared to 0.18 yuan in the same period last year [8]